Publication | Open Access

Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non–Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations

Non–small-cell Lung CancerOncologyMedicinePharmacotherapyAnti-cancer AgentCancer TreatmentPhase 2PharmacologyRadiation OncologyLung CancerChemotherapy-naive Patients